Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05091060 · ClinicalTrials.gov registry record · NA
Effect of the Erchonia® HLS™ for the Relief of Tinnitus Symptoms
A NA study, sponsored by Erchonia Corporation.
- Terminated
- Registry status
- NA
- Development phase
- 5
- Enrollment target
NCT05091060: Clinical Trial NA study, sponsored by Erchonia Corporation.
NCT05091060 is a NA study that was terminated before completion, run by Erchonia Corporation. The registered enrollment target is 5 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05091060, a NA study, was terminated before completion, sponsored by Erchonia Corporation.
- TERMINATED
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study is to see if applying red low-level laser light can help to reduce tinnitus symptoms
Primary Outcome
The Tinnitus Handicap Inventory (THI) is a 25-item questionnaire to assess how tinnitus affects an individual's life. Each question is responded to as 'yes' (4 points); 'sometimes' (2 points) or 'no' (0 points). The individual scores for the 25 questions are added to get a total THI score from 0 to 100. The higher the total THI score, the greater the negative impact tinnitus has on the individual's life. Change in total THI score is calculated as total THI score after the eight week procedure ad
Interventions
- DEVICE Erchonia HLS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2021-06-10 |
| Est. Completion | 2022-03-14 |
| Phase | NA |
Why NCT05091060 stopped before completion
NCT05091060 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Erchonia HLS is the first listed.
NCT05091060 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05091060 about?
NCT05091060 is a clinical study titled "Effect of the Erchonia® HLS™ for the Relief of Tinnitus Symptoms". This study is to see if applying red low-level laser light can help to reduce tinnitus symptoms
What is the current status of trial NCT05091060?
This trial is currently terminated. It is a NA study. The enrollment target is 5 participants. The study started on 2021-06-10. Estimated completion is 2022-03-14.
What interventions are being tested in trial NCT05091060?
The interventions under investigation include: Erchonia HLS (DEVICE).
Who is sponsoring clinical trial NCT05091060?
This trial is sponsored by Erchonia Corporation, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05091060's enrollment target sits among peer trials
5 1988th of 2000 higher than 5 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI